Aurobindo Pharma Limited announced today that its wholly owned subsidiary, CuraTeQ Biologics, had received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)to its bevacizumab biosimilar, Bevqolva. Bevqolva is the product available as a 25 mg/mL concentrate for infusion for two single-use vial sizes: 4 mL (100 mg) and 16 mL (400 mg), to be administered intravenously.

In the exchange filing, the company shared, “CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma Limited, is pleased to announce that it has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version”.

Bevacizumab is used to treat various cancers, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and ovarian cancer.

Headquartered in Hyderabad, India, CuraTeQ Biologics is dedicated to improving patient outcomes by providing high-quality, cost-effective biosimilars. The company focuses on developing treatments for cancer and autoimmune diseases, with a robust pipeline of 14 biosimilars targeting immunology and oncology. CuraTeQ offers end-to-end capabilities, from bulk drug production to finished, packaged drug products.